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INEFFECTIVE ERYTHROPOIESIS IN RECIPIENT PRECURSOR CELLS FOL-
LOWING NON-MYELOABLATIVE STEM CELL TRANSPLANTATION IN
PATIENTS WITH SEVERE SICKLE CELL ANEMIA
Wu, C.J.1,2, Rogers, S.A.1, Kutok, J.3, Krishnamurti, L.4, Hochberg,
E.P.1,2, Biernacki, M.1, Antin, J.H.1,2, Ritz, J.1,2 1. Department of
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2. De-
partment of Medicine, Brigham and Women’s Hospital, Boston, MA; 3.
Department of Pathology, Brigham and Women’s Hospital, Boston, MA;
4. Pediatric Hematology/Oncology/BMT, Children’s Hospital of Pitts-
burgh, Pittsburgh, PA.
After nonmyeloablative (NMA) stem cell transplantation (SCT),
we observed greater clinical improvement in sickle cell disease
(SCD)-associated symptoms than anticipated by the degree of
chimerism established by routine genotyping of marrow or periph-
eral blood cells in some patients. We hypothesized that RBC
chimerism would provide a more accurate assessment of functional
donor hematopoiesis. -globin RNA pyrosequencing can be used
to quantify erythroid-speciﬁc lineage chimerism following trans-
plant. In this method, direct quantitative sequencing of the sickle
mutation in -globin RNA serves as an informative locus to dis-
tinguish between recipient and donor erythropoiesis. This analysis
was performed on serial samples collected from 3 patients with
severe SCD with HLA-matched related donors who underwent
NMA-SCT. -globin RNA chimerism in peripheral blood (PB)
and marrow (BM) was compared to total genomic DNA chimerism
and DNA chimerism of phenotypically deﬁned erythroid lineage
precursor cells. All patients demonstrated stable mixed donor
DNA chimerism in the ﬁrst 60-100 days, at levels of 25-30%,
40-50% and 56-60% in Pts 1, 2 and 3, respectively, with no
difference between PB and BM levels. DNA chimerism of BM
erythroid precursors, determined by Y chromosome FISH and
ABO staining in Pts 1 and 2, were identical to total BM gDNA
chimerism. In contrast, all 3 patients demonstrated a 2 fold
greater level of -globin RNA chimerism in PB and marrow
compared with gDNA chimerism, with 45/55%, 100/100% and
100/100% BM/PB% donor -globin RNA measured in Pts 1, 2
and 3, respectively. The consistently increased levels of donor
derived -globin RNA detected in marrow samples, compared to
the lower levels of erythroid DNA chimerism suggest that recipi-
ent erythroid precursor cells with sickle hemoglobin do not effec-
tively mature into peripheral RBC. In patients with mixed hema-
topoietic chimerism after NMA-SCT, donor erythroid precursor
cells have a maturation advantage that allows for greater donor
contribution to overall erythropoiesis. This advantage is likely
further accentuated by the shortened survival of recipient RBC.
Further studies are underway to characterize the mechanisms that
lead to ineffective SCD erythropoiesis in these patients.
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BEAM ALLOGENEIC TRANSPLANT IN PATIENTS FAILING AUTOLOGOUS
TRANSPLANTATION FOR HODGKIN’S DISEASE OFFERS AN OPPORTU-
NITY FOR LONG-TERM SURVIVAL
Stilwill, J.F., Toor, A.A., Rodriguez, T.E., Strupeck, J., Parthasarathy,
M., Stiff, P.J. Loyola University Medical Center, Maywood, IL.
While the current standard of care for refractory Hodgkin’s
disease is an autologous stem cell transplant, patients who fail this
form of therapy usually receive only palliative therapy. With the
possibility of reduced-intensity allografts decreasing toxicity seen
previously with ablative transplants and a presumed graft-versus-
lymphoma effect, we began a program in 2000 to perform alloge-
neic transplants with BEAM conditioning in patients with
Hodgkin’s disease who had failed autologous transplant. We have
treated 13 patients to date using graft-versus-host-disease
(GVHD) prophylaxis with mini-methotrexate and FK-506 with
early weaning from day 60 to day 80. The median age at allograft
was 35 (range: 21 to 48). Median time from diagnosis to allograft
was 69 months (range: 12 to 172 months), from autograft to relapse
was 11 months (range: 0 to 44 months) and from relapse following
autograft to allograft was 31 months (range: 2 to 105 months).
Median number of relapses from diagnosis was 4 (range: 2 to 6). Of
the 13 patients, 11 had chemoresistant disease, 8 had bulky disease
(bulk 2 cm in diameter), 3 had extranodal disease and 5 had
relapsed disease in a prior radiation port at allograft. Patients
received either matched sibling peripheral blood stem cells (5),
partially matched sibling bone marrow (1), or matched unrelated
bone marrow (7). At a median of 29 months from allograft (range:
2 to 41 months), 6 of 13 patients (46%) are alive and all are
currently in complete remission (CR). Of the 7 patients that died,
1 died of sepsis during hospitalization, 2 expired without evidence
of disease (GVHD; CHF), and 4 expired due to progressive dis-
ease. Nine patients developed chronic GVHD including 5 of 6 in
CR (1 too early). Two patients received donor lymphocyte infu-
sions (DLI) following relapse resulting in transient improvement in
one and a CR in the other. Given that 46% are alive with no
evidence of disease, this compares favorably with accepted indica-
tions for allogeneic transplant after failed autograft for Non-
Hodgkin’s lymphoma. Allogeneic transplant offers a signiﬁcant
opportunity for long-term survival in patients with Hodgkin’s
disease that have failed autologous transplant, even those with
chemoresistant disease and without matched related donors, and
should be considered an important option in all such patients.
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SINGLE INSTITUTION EXPERIENCE WITH HHV6 INFECTIONS IN THE
PEDIATRIC HSCT PATIENTS
Olson, E.A.1, Chiang, K.Y.1, Haight, A.E.2, Bowman, L.2 1. Children’s
Healthcare of Atlanta, Atlanta, GA; 2. Emory University, Atlanta, GA.
Reactivated Herpes family viral infections continue to cause
morbidity and mortality during hematopoietic stem cell transplant
(HSCT). Routine monitoring and prophylactic or preemptive
therapy for CMV during the peritransplant period are now ac-
cepted standards of care in allogeneic HSCT. Other viral infec-
tions such as Human Herpesvirus 6 (HHV6) have been increas-
ingly identiﬁed as a signiﬁcant cause of morbidity during HSCT.
New technology with quantitative PCR testing permits more rapid
diagnosis of HHV6 reactivation. During an eight-month period at
our institution ﬁve out of nine allogeneic HSCT patients (55%)
were diagnosed with HHV6 infection, no autologous patients
tested positive. All received acyclovir prophylaxis. Graft source and
indication for HSCT were: one matched sibling with MDS; one
unrelated cord blood for infant leukemia; and three T-cell depleted
matched unrelated transplants for CML. Three of the patients
presented with respiratory distress with diffuse alveolar hemor-
rhage. Bronchial alveolar lavage (BAL) was positive for HHV6 by
PCR on all three patients. The other two had central nervous
system (CNS) manifestation; one had a seizure and the other had
progressive mental status changes. Spinal ﬂuids from both patients
were positive for HHV6 by PCR. Four of the patients were treated
with Ganciclovir; the ﬁfth patient received Foscarnet since this
patient was already on Ganciclovir for CMV infection. Two of the
patients responded initially to the Ganciclovir with a decrease in
HHV6 quantitative PCR level, but the PCR increased and symp-
toms worsened requiring a switch to Foscarnet. The other three
continued to have progressive deterioration from the HHV6.
HHV6 was the cause of death in all ﬁve patients. These case
reports demonstrate the emergence of HHV6 as a signiﬁcant viral
pathogen in allogeneic HSCT patients. Vigilant clinical observa-
tion with routine monitoring of HHV6 by a sensitive and reliable
test and prompt treatment with appropriate antiviral agents may
allow improved outcome for this deadly viral infection.
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T CELL (CD3) CHIMERISM AFTER NON-MYELOABLATIVE ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (NMHSCT)
Sobecks, R., Theil, K., Rybicki, L., Kuczkowski, E., Warshawsky, I.,
Tubbs, R., Kalaycio, M., Pohlman, B., Andresen, S., Bolwell, B.J. The
Cleveland Clinic Foundation, Cleveland, OH.
Poster Session I
41BB&MT
NMHSCT may potentially achieve a graft-vs-malignancy effect
mediated by donor-derived T cells. From 1/10/00 through 9/9/03
we treated 50 pts with NMHSCT using a preparative regimen of
ﬂudarabine 30 mg/m2/d IV on days -5, -4, -3, and total body
irradiation 200 cGy on day -1. Diagnoses included 12 NHL, 9
AML, 7 CML, 6 myeloma, 4 MDS, 4 MFB, 4 renal cell carcinoma,
2 CLL and 2 Hodgkin’s lymphoma. The median CD34 and
CD3 cell doses infused were 6.64 x 106/kg and 3.74 x 108/kg,
respectively. 14 pts had matched unrelated donors (MUD). T cell
(CD3) chimerism was monitored by short tandem repeat analy-
sis. Mixed chimerism (MC) consisted of1% to99% host DNA.
Thirty (60%) pts achieved T cell complete donor chimerism
(CDC) at a median of 63 days (range 14-400) with 7 (50%) MUD
pts and 23 (64%) related donor pts achieving CDC. 32 (64%) pts
developed acute GVHD at a median of 34 days (range 8-97) with
12 grade 1, 7 grade 2, 8 grade 3 and 5 grade 4. At the time acute
GVHD developed the median % of donor T cell DNA was 90%
(range 37-100) and only 11 (34%) of these pts had achieved CDC.
19 (38%) pts developed chronic GVHD at a median of 196 days
(range 104-531) and at the time of its detection 15 (79%) pts had
achieved CDC. GVHD developed in 9 (64%) MUD pts and in 29
(81%) related donor pts. There were 19 (38%) pts with either
disease relapse/progression at a median of 117 days (range 17-639)
which occurred in 8 pts with CDC, in 8 pts with MC and in 3 pts
with graft failure. 13 (26%) pts achieved CR with 9 having stable
CDC, 3 with stable MC without ever achieving CDC and 1 pt had
a graft failure. 6 pts achieved a PR with 3 having stable CDC, 2
with MC without ever achieving CDC, and 1 pt not evaluable for
T cell chimerism. At 10 months median follow-up (range 0.7-42
mos) 25 (50%) pts have died. 11 (44%) of these pts had stable
CDC, 7 never achieved CDC with 3 of them proceeding to a full
ablative HSCT, 5 achieved CDC which reverted to MC and then
back to stable CDC, 1 achieved CDC but due to conversion to MC
underwent a full ablative HSCT, and 1 pt was not evaluable for T
cell chimerism. We conclude that post-transplant monitoring of T
cell (CD3) chimerism is important to allow for immune manip-
ulation to maintain a state of donor-host tolerance in order to
prevent graft rejection. Acute GVHD commonly occurs after
NMHSCT without achieving CDC, whereas pts who develop
chronic GVHD as well as those who attain disease responses are
more likely to have CDC.
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ONE HUNDRED CHILDREN UNDERGOING ALLOGENEIC BONE MAR-
ROW TRANSPLANTATION WITH CYCLOPSPORIN (NEORAL) BY MOUTH
Mazzolari, E.1, Porta, F.1, Forino, C.1, Gandellini, F.1, Maffeis, B.1,
Caldiani, C.1, Rodriguez, C.1, Lanfranchi, A.2 1. Dept of Pediatrics,
Brescia, Italy; 2. Laboratorio Trapianti, Brescia, Italy.
Bone marrow transplantation is performed as an elective therapy
in children affected by onco-haeamtological and genetic diseases.
Since 1996 we have grafted 100 children affected by onco-haeam-
tological diseases from haploidentical (14), matched unrelated (60),
identical (26) by using cyclosporin (Neoral) by mouth. In all cases
cyclosporin have been administred all through the transplant, with-
out using the drug IV. All patients receive preaparative chemio-
therapy regimens before transplant, among our patients , 25 af-
fected by acute leukemias received total body irradiation. Mean age
at transplant was 3,5 years (age range 1 month-12 years). In all
cases cyclosporin levels were within the normal range. Incidence of
acute GVHD grade III/IV was 12%, chronic GVHD 4 %.Trans-
plant related mortality was 18%. None of the children presented
side effects related by cyclosporin administration. Our experience
demonstraed that in pediatrics there is no need of intravenous
administrationof cyclopsorin.
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HAPLOIDENTICAL TRANSPLANTS FROM POSITIVELY SELECTED BONE
MARROW HAEMATOPOIETIC STEM CELLS: REPORT OF 20 CASES
Lanfranchi, A.1, Verardi, R.1, Baggio, E.1, Mazzolari, E.2, Porta, F.2
1. Laboratorio Trapianti, Brescia, Italy; 2. Clinica Pediatrica, Brescia,
Italy.
Genetic diseases affecting haematopoietic and immune systems
can be cured by bone marrow transplantation (BMT). Haploiden-
tical BMT is the treatment of choice in many cases since is uneven
to have an healthy matched family donor in family trees affecte by
a genetic disease. Moreover the search of matched unrelated donor
can take long (3-6 months)and succeed in 70% of the cases. Since
1983 haploidentical traplants have been performed by T cell de-
pletion. In our experience we have performed 40 haploidentical
transplants by Campath 1M bone marrow T cell depletion in
children affected by genetic diseases from 1991 to 1996. The
overall engraftment rate was 60%, but the event free survival did
not exceeded 40%. Camtpath 1M recognized CD52 positive cells,
that meant T cells, B cells, monocytes, plasmacells and approxi-
mately 50% of CD34 cells. Reasons of relative unsuccess were
maybe related to a profound depltion of accesory cells within the
bone marrow suspension. Since 1996 we utilized Clinimacs clinical
device to perform positive selection of haetopoietic stem cells.
Since we are treating genetic diseases the children affected have a
mean age of 2,5 years, therefore the weight at transplant do not
exceed 10 kg. We have performed 20 haploidentical transplants
positively selecting haematopoietic stem cells from bone marrow.
The children were affected by severe combined immunodeﬁcine-
cies(SCID) and other primary immunodeﬁciencies. The mean
yield of stem cells was 75% of the initial stem cell count, while the
purity of the stem cells was 91. 8%. Engraftment rate was 90%
with a mean time for complete immune reconstitution that did not
exceed 3 months.
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ALLOGENEIC STEM CELL TRANSPLANTATION FOR THE TREATMENT OF
12 PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA IN
BRAZIL
Bonﬁm, C.M.S., Bitencourt, M.A., Moreira, V.A., Setubal, D.C.,
Lorenzatto, C., Ruiz, J., Neves, H., de Medeiros, C.R., Zanis-Neto, J.,
Pasquini, R. Children’s Hospital Oakland Research Incstitute, Oakland,
CA.
Background: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a
clonal disorder caused by acquired mutations of the PIG-A gene.
Stem Cell Transplantation (SCT) with an HLA identical sibling is
potentially curative for young patients with severe pancytopenia,
massive hemolysis or serious thrombotic complications. Material
and Methods: We performed a retrospective analysis of 12 pts who
underwent a non T cell depleted SCT from HLA identical donors
at our institution between 03/1988 and 04/2003. Indication for
SCT: severe pancytopenia: 9 pts, thrombosis: 2 pts and hemolysis:
1 pt. The conditioning regimen consisted of BU12mg/kg  CY
120mg/kg: 8 pts (1 pt received BU16mg/kg), BU 8mg/kg  Flu-
darabine 125mg/m2: 1 pt and CY 200mg/kg: 1 pt. Bone marrow
was the stem cell source for 11 pts while 1 pt received peripheral
blood. All but one pt received methotrexate cyclosporine as graft
versus host disease (GVHD) prophylaxis. All pts received prophy-
lactic antibiotics with ﬂuconazol, sulfamethoxazole-trimethoprim
and acyclovir according to common practice. Results: Pts charac-
teristics: Median age at transplantation: 27, 5 years (range: 14-42
yr); Gender: 4F/8M. Time from diagnosis to SCT was a median of
16 months (range: 2-133m). A median of 22, 5 UI of blood
transfusions were given before transplant (range: 8-200 UI). Total
nucleated cell infused: 1, 72-12, 3 x 108/kg (Median: 2, 74). All pts
surviving more than 28 days engrafted at a median of 18 days
(range: 15-25 days). Mucosytis grade III-IV occurred in 6 pts. Two
patients developed grade III-IV acute GVHD. Two pts had exten-
sive chronic GVHD : One progressed after A-GVHD and the
other one had a de novo extensive C-GVHD. No pt developed
veno-occlusive disease. Eight pts are alive and well with a median
follow up of 3038 days (range: 176-5662). Four pts (Median age:
36,5yr) died on day 10, 11, 71 and 330 after SCT. Causes
of death included infection (2) and GVHD (2).Estimated 9 year
overall survival is 66% (95% CI). Conclusion: We conclude that
pts with PNH and life threatening complications can achieve long
term survival after this conditioning regimen. These pts can be
offered an allogeneic STC if they have an HLA identical sibling
and develop severe pancytopenia, hemolysis or recurrent throm-
bosis.
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